T1	Premise 983 1123	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
T2	Premise 1124 1186	Group differences were smaller within the psychosocial domain,
T3	Premise 1187 1249	although trends were seen in favour of the chemotherapy group.
T4	Premise 1250 1326	No significant differences were seen in favour of the supportive care group,
T5	Premise 1327 1348	except for hair loss.
T6	Premise 1349 1502	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
T7	Premise 1503 1623	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
T8	Premise 1624 1661	No treatment-related deaths occurred.
T9	Claim 1662 1804	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
R1	Partial-Attack Arg1:T5 Arg2:T4	
R2	Support Arg1:T1 Arg2:T9	
R3	Partial-Attack Arg1:T3 Arg2:T2	
R4	Support Arg1:T6 Arg2:T9	
R5	Support Arg1:T7 Arg2:T9	
